| Description | Bococizumab(PF-04950615) is a humanized mAb against PCSK9 and an inhibitor of the synthesis of PCSK9 in the liver that reduces the amount of low-density lipoprotein cholesterol (LDL-C) in the blood.Bococizumab is used to treat hypercholesterolemia. |
| In vivo | Bococizumab (0, 10, 30和100 mg/kg; i.v.; 孕期Sprague-Dawley (SD)大鼠) 降低母体和胎儿的胆固醇水平，并显示出良好的耐受性，对卵巢或子宫参数无影响。[2] |
| Synonyms | RN316, PF-04950615 |
| molecular weight | N/A |
| CAS | 1407495-02-6 |
| Storage | store at low temperature | store at -20°C |
| References | 1. Koutaro Yokote, et al. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Randomized, Placebo-Controlled, Dose-Ranging Study. Circ J. 2017 Sep 25;81(10):1496-1505. 2. Sarah N Campion, et al. Decreased maternal and fetal cholesterol following maternal bococizumab (anti-PCSK9 monoclonal antibody) administration does not affect rat embryo-fetal development. Regul Toxicol Pharmacol. 2015 Nov;73(2):562-70. |